Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
Patricia García‐Sanz, Johannes M. F. G. Aerts, Rosario Moratalla
Movement Disorders (2020) Vol. 36, Iss. 5, pp. 1070-1085
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
Rosalía Fernández‐Calle, Sabine C. Konings, Javier Frontiñán-Rubio, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 140
AAV-based in vivo gene therapy for neurological disorders
Qinglan Ling, Jessica A. Herstine, Allison M. Bradbury, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 10, pp. 789-806
Closed Access | Times Cited: 86
Advances in understanding the function of alpha-synuclein: implications for Parkinson’s disease
Paolo Calabresi, Giulia Di Lazzaro, Gioia Marino, et al.
Brain (2023) Vol. 146, Iss. 9, pp. 3587-3597
Open Access | Times Cited: 57
Sleep disorders cause Parkinson's disease or the reverse is true: Good GABA good night
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Ali K. Albuhadily, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 3
Open Access | Times Cited: 16
Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects
Bin Tong, Yaoqi Ba, Zhengyang Li, et al.
Neurobiology of Disease (2024) Vol. 196, pp. 106505-106505
Open Access | Times Cited: 16
Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments
Matthew E. Gegg, Elisa Menozzi, Anthony H.V. Schapira
Neurobiology of Disease (2022) Vol. 166, pp. 105663-105663
Open Access | Times Cited: 48
A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 2, pp. 673-688
Closed Access | Times Cited: 27
Impaired Cholesterol Metabolism, Neurons, and Neuropsychiatric Disorders
So Yeong Cheon
Experimental Neurobiology (2023) Vol. 32, Iss. 2, pp. 57-67
Open Access | Times Cited: 24
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Xuxiang Zhang, Heng Wu, Beisha Tang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets
N Wang, Peng Sun, Qi-Qi Shen, et al.
Molecular Neurobiology (2025)
Closed Access | Times Cited: 1
The potential role of cholesterol in Parkinson’s disease neuropathology: perpetrator or victim
Mohammed Alrouji, Hayder M. Al‐kuraishy, Abdul-karim Abd Ali Al-Mahammadawy, et al.
Neurological Sciences (2023) Vol. 44, Iss. 11, pp. 3781-3794
Closed Access | Times Cited: 17
Treatment with β-sitosterol ameliorates the effects of cerebral ischemia/reperfusion injury by suppressing cholesterol overload, endoplasmic reticulum stress, and apoptosis
Xiuling Tang, Tao Yan, Saiying Wang, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 3, pp. 642-649
Open Access | Times Cited: 16
Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson’s disease
Jae-Bong Kim, Soo‐Jeong Kim, M. L. So, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116442-116442
Open Access | Times Cited: 6
Consequences and mechanisms of myelin debris uptake and processing by cells in the central nervous system
Grace Hammel, Sandra Zivkovic, Maryam Ayazi, et al.
Cellular Immunology (2022) Vol. 380, pp. 104591-104591
Open Access | Times Cited: 27
GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders
Macarena Martı́nez-Bailén, Francesca Clemente, Camilla Matassini, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 823-823
Open Access | Times Cited: 23
The Endo-lysosomal System in Parkinson’s Disease: Expanding the Horizon
Amitha Muraleedharan, Benoît Vanderperre
Journal of Molecular Biology (2023) Vol. 435, Iss. 12, pp. 168140-168140
Open Access | Times Cited: 14
Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories
Colin Birkenbihl, Ashar Ahmad, Nathalie J. Massat, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 13
New insights on neurodegeneration triggered by iron accumulation: Intersections with neutral lipid metabolism, ferroptosis, and motor impairment
Athina Maniscalchi, Oriana N. Benzi Juncos, Melisa A. Conde, et al.
Redox Biology (2024) Vol. 71, pp. 103074-103074
Open Access | Times Cited: 5
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Samo Ribarič
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4358-4358
Open Access | Times Cited: 5
Modulation of cholesterol metabolism with Phytoremedies in Alzheimer’s disease: A comprehensive review
Sushruta Koppula, Nitu L. Wankhede, Shivkumar S. Sammeta, et al.
Ageing Research Reviews (2024) Vol. 99, pp. 102389-102389
Closed Access | Times Cited: 5
Patient-centered brain transcriptomic and multimodal imaging determinants of clinical progression, physical activity, and treatment needs in Parkinson’s disease
Quadri Adewale, Ahmed Faraz Khan, Sue‐Jin Lin, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson’s disease
Lijun Dai, Jiannan Wang, Lanxia Meng, et al.
PLoS Biology (2025) Vol. 23, Iss. 2, pp. e3002974-e3002974
Open Access
Autophagy as a gateway for the effects of methamphetamine: From neurotransmitter release and synaptic plasticity to psychiatric and neurodegenerative disorders
Fiona Limanaqi, Carla L. Busceti, Roberta Celli, et al.
Progress in Neurobiology (2021) Vol. 204, pp. 102112-102112
Open Access | Times Cited: 28
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Bruno Dutra Arbo, Lúcia Emanueli Schimith, Michele Goulart dos Santos, et al.
European Journal of Pharmacology (2022) Vol. 919, pp. 174800-174800
Open Access | Times Cited: 20
Recent research progress on metabolic syndrome and risk of Parkinson’s disease
Linyi Li, Shufen Liu, Jian-long Zhuang, et al.
Reviews in the Neurosciences (2022) Vol. 34, Iss. 7, pp. 719-735
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top